Flanigan R - Search Results

1

Diversity of the midstream urine microbiome in adults with chronic kidney disease.

Kramer H, Kuffel G, Thomas-White K, Wolfe AJ, Vellanki K, Leehey DJ, Bansal VK, Brubaker L, Flanigan R, Koval J, Wadhwa A, Zilliox MJ. Kramer H, et al. Among authors: flanigan r. Int Urol Nephrol. 2018 Jun;50(6):1123-1130. doi: 10.1007/s11255-018-1860-7. Epub 2018 Apr 12. Int Urol Nephrol. 2018. PMID: 29651696 Free PMC article.

2

Urinary incontinence and diuretic avoidance among adults with chronic kidney disease.

Patel M, Vellanki K, Leehey DJ, Bansal VK, Brubaker L, Flanigan R, Koval J, Wadhwa A, Balasubramanian N, Sandhu J, Kramer H. Patel M, et al. Among authors: flanigan r. Int Urol Nephrol. 2016 Aug;48(8):1321-1326. doi: 10.1007/s11255-016-1304-1. Epub 2016 May 21. Int Urol Nephrol. 2016. PMID: 27209426

3

The effect of chronic renal insufficiency on cyclosporine nephrotoxicity.

Kinzler GJ, Holmes EW, Reckard CR, Jablokow VR, Fresco R, Flanigan RC. Kinzler GJ, et al. Among authors: flanigan rc. J Urol. 1991 Jan;145(1):179-83. doi: 10.1016/s0022-5347(17)38286-1. J Urol. 1991. PMID: 1984088

4

Renal tumors in young adults.

Eggener SE, Rubenstein JN, Smith ND, Nadler RB, Kontak J, Flanigan RC, Waters WB, Picken M, Campbell SC. Eggener SE, et al. Among authors: flanigan rc. J Urol. 2004 Jan;171(1):106-10. doi: 10.1097/01.ju.0000099028.95679.52. J Urol. 2004. PMID: 14665855

5

Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.

Bajic P, Flanigan RC, Joyce CJ, Clark JI. Bajic P, et al. J Urol. 2019 Mar;201(3):453-454. doi: 10.1016/j.juro.2018.09.050. J Urol. 2019. PMID: 30266335 No abstract available.

6

Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma-Are There Any Favorable Risk Patients?

Patel HD, Clark JI, Flanigan RC. Patel HD, et al. J Urol. 2021 Jul;206(1):4-6. doi: 10.1097/JU.0000000000001656. Epub 2021 Feb 9. J Urol. 2021. PMID: 33560871 No abstract available.

7

Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function.

Mulhall JP, Slovick R, Hotaling J, Aviv N, Valenzuela R, Waters WB, Flanigan RC. Mulhall JP, et al. Among authors: flanigan rc. J Urol. 2002 Mar;167(3):1371-5. doi: 10.1016/s0022-5347(05)65303-7. J Urol. 2002. PMID: 11832735

8

Risk assessment for occult malignancy in the prostate before radical cystectomy.

Kefer JC, Voelzke BB, Flanigan RC, Wojcik EM, Waters WB, Campbell SC. Kefer JC, et al. Urology. 2005 Dec;66(6):1251-5. doi: 10.1016/j.urology.2005.07.006. Urology. 2005. PMID: 16360452

9

An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer.

Flanigan RC, Polcari AJ, Shore ND, Price TH, Sims RB, Maher JC, Whitmore JB, Corman JM. Flanigan RC, et al. J Urol. 2013 Feb;189(2):521-6. doi: 10.1016/j.juro.2012.09.029. Epub 2012 Dec 14. J Urol. 2013. PMID: 23253957 Clinical Trial.

10

Urinary Exosomes: The Potential for Biomarker Utility, Intercellular Signaling and Therapeutics in Urological Malignancy.

Franzen CA, Blackwell RH, Foreman KE, Kuo PC, Flanigan RC, Gupta GN. Franzen CA, et al. J Urol. 2016 May;195(5):1331-1339. doi: 10.1016/j.juro.2015.08.115. Epub 2015 Dec 20. J Urol. 2016. PMID: 26714199 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

260 results

Search Page